Peginterferon and other interferons for hepatitis C - [Medication] - Quest Diagnostics Patient Health Library 2 , 3 How Well It Works One study found that 54% to 56% of people who took a high dose of peginterferon alfa -2b (Peg-Intron) with ribavirin no longer had the virus in their blood 6 months after treatment, compared with 44% to 47% of people who took either a lower-dose peginterferon with ribavirin or standard interferon with ribavirin.
Combination antiviral therapy for hepatitis C - [Medication] - Quest Diagnostics Patient Health Library Topic Contents - Examples - How It Works - Why It Is Used - How Well It Works - Side Effects - What To Think About - References Combination antiviral therapy for hepatitis C - [Medication] - Quest Diagnostics Patient Health Library Combination antiviral therapy for hepatitis C - [Medication] - Quest Diagnostics Patient Health Library antiviral, antiviral agents, Antiviral Drugs,...
Press Release - November 15, 2005 FOR IMMEDIATE RELEASE CONTACTS: Jerry Parrott Vice President, Corporate Communications 301/315-2777 Kate de Santis Director, Investor Relations 301/251-6003 HUMAN GENOME SCIENCES REPORTS INTERIM RESULTS OF PHASE 2 CLINICAL TRIAL OF ALBUFERON™ IN COMBINATION WITH RIBAVIRIN IN TREATMENT-EXPERIENCED HEPATITIS C PATIENTS ROCKVILLE, Maryland – November 15, 2005 –...
Press Release - October 25, 2005 FOR IMMEDIATE RELEASE CONTACTS: Jerry Parrott Vice President, Corporate Communications 301/315-2777 Kate de Santis Director, Investor Relations 301/251-6003 HUMAN GENOME SCIENCES COMPLETES PATIENT ENROLLMENT IN A PHASE 2B CLINICAL TRIAL OF ALBUFERON™ IN COMBINATION WITH RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C ROCKVILLE, Maryland – October 25,...
Human Genome Sciences: Albuferon Pharmacokinetics and pharmacodynamics of pegylated interferon alfa -2a or alfa -2b with ribavirin in treatment naive patients with genotype 1 chronic hepatitis C.Peginterferon -alpha-2a (40 kD): A Review of Its Use in the Management of Chronic Hepatitis C.
Viramidine (Valeant Pharmaceuticals), a ribavirin prodrug for the improved treatment of hepatitis C (HCV) infection: reduced - - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
Cover 0519.qxd This weeks UK Patents and Design Journal (PDJ) contained details of one SPC grant and notification of three SPCs entering into force.ribavirin on EP643970 entered into force April 16 th and expires in April 2010.peginterferon products, whilst in January 2003 ICN,...
author: GWhite
Cover 0519.qxd page 1
author: GWhite
Gazette Weekly Highlights News - Thomson Scientific Thomson.com - - - - - Advanced Search - - - EN : JP : CN : KR -- - - - Current Patents Gazette - Weekly Highlights News The gazette weekly highlights focuses on patent-related issues making the headlines, on noteworthy new applications, and on litigation and legislation affecting the industry.
Press Release - May 17, 2005 The results demonstrate that Albuferon (albumin-interferon alpha) exhibits more antiviral activity at clinically achieved serum levels than standard interferon alpha or the modified interferons, Pegasys (peginterferon alfa -2a) and Peg-Intron (peginterferon alfa -2b).ribavirin is underway in...
Press Release - June 1, 2005 The fourth treatment group will serve as the active control group and will receive weekly 180-mcg doses of subcutaneously administered Pegasys (peginterferon alfa -2a). ribavirin, which show that Albuferon can be administered safely...
Press Release - April 13, 2005 5 Reductions in viral load of - 2 log are reported in approximately 42% of genotype 1 HCV patients treated with pegylated interferon alpha products in combination with ribavirin.
No Title The specific mechanism by which merimepodib enhances ribavirin activity is not known, but it has been suggested that merimepodib may increase the likelihood of ribavirin incorporation into viral RNA during replication, resulting either in decreased viral replication or in the production of immature or defective viral particles.
author: Windows 9x/NT/2000/XP User
subject: None
No Title page 60
author: Windows 9x/NT/2000/XP User
subject: None
No Title page 12
author: Windows 9x/NT/2000/XP User
subject: None
Press Release - February 16, 2005 FOR IMMEDIATE RELEASE CONTACT: Jerry Parrott Vice President, Corporate Communications 301/315-2777 Kate de Santis Director, Investor Relations 301/251-6003 HUMAN GENOME SCIENCES COMPLETES ENROLLMENT IN A PHASE 2 CLINICAL TRIAL OF ALBUFERON™ IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C - Preliminary data demonstrate sufficient antiviral activity to support larger Phase...
Vertex Pharmaceuticals Press Release May 25, 2004 Vertex Pharmaceuticals Announces Plans for the METRO Study: Triple Combination of Merimepodib, Pegasys® and Copegus® in Hepatitis C Patients - Roche Agrees to Provide Pegasys and Copegus for Phase IIb Clinical Trial - Cambridge, MA, May 25, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today the design of a Phase IIb clinical study that it plans to...
Vertex Pharmaceuticals Press Release July 26, 2004 Vertex Pharmaceuticals Reports Second Quarter 2004 Financial Results and Provides Clinical Update --Company on Track to Achieve 2004 Milestones-- Cambridge, MA, July 26, 2004 --Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the three and six months ended June 30, 2004.
Database P P - investigational drugs, therapies and vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products To purchase documents on-line click on- -link attached to selected document!- The fee is $15 per document Documents are delivered by e-mail...
Press Release - November 30, 2004 (Nasdaq: HGSI) announced today that it has begun dosing patients in a Phase 2 clinical trial of Albuferon™ (albumin-interferon alpha) in combination with ribavirin to evaluate the safety, tolerability and efficacy of Albuferon in patients with chronic hepatitis C who failed to respond to previous interferon alpha-based treatment regimens.
Contents Vol. 22, No. 7, 2004 22, No
author: Adis International Limited
subject: PharmacoEconomics
Therapeutic Biological Approvals 97 South Street Hopkinton, MA 01748 License 1258 02/05/1999 PEGASYS Peginterferon alfa -2a Treatment of adults with chronic hepatitis C who have compensated liver disease and who have not been previously treated with interferon alfa 103964 / 0 Hoffman-La Roche, Inc 340 Kingsland Street Nutley, NJ 07110-1199 License 0136 10/16/2002 PEGASYS Peginterferon ...
Office of Drug Safety: Patient Labeling and Risk Communitation Food and Drug Administration • Center for Drug Evaluation and Research Office of Drug Safety Search Patient Labeling and Risk Communication FDA-Approved Patient Labeling Patient Package Inserts.- For some prescription medicines, FDA approves special patient materials to instruct patients about the safe use of the product
author: PhillipsJ
Antiviral Drugs Advisory Committee Meetings (None held to date) Previous Years 2003 ---- 2002 --- 2001 ---- 2000 ---- 1999 ---- 1998 --- 1997 ---- 1996 2002 Meetings (link to transcripts and other meeting information) Date: 11/14/2002 Topic:- The committee will discuss biologics license application 125061/0, peginterferon alfa -2a copackaged with ribavirin, new drug application 21-511, Hoffmann-La Roche,...
Approved Biotechnology Drugs, 2000 - Hereditary tyrosinemia type 1 - January 2002 Pediarix TM (diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B [recombinant] and inactivated polio-virus vaccine combined) - GlaxoSmithKline - Prevention of diphtheria, tetanus, pertussis, hepatitis B and polio - December 2002 Pegasys ® (peginterferon alfa -2a) - Roche and Inhale...
